AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01394640 — intervention group
Intervention type: BIOLOGICAL
Intervention: Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
Description: The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
Study NCT03997292 — intervention group
Intervention type: DRUG
Intervention: Alteplase
Description: According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
Study NCT01217541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education and Supervision
Description: Implementation of Scales in the care of patients with dementia in nursing home units with focus on person-centred care. Supervision of caregivers on a regular basis.
Study NCT01217541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: A control group of nursing home units that do not get any form of active intervention
Study NCT04389177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Neoadjuvant period:preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks.~Da Vinci robot radical surgery: Before surgery, head/abdomen/chest CT scan, type B ultrasonic, upper gastrointestinal contrast, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 4-6 weeks after last neoadjuvant treatment finished.~Adjuvant period: Adjuvant treatment with pembrolizumab 200mg every 3 weeks (6 cycles) should be performed within 3-6 weeks after surgery if the surgical pathology result is not pCR. abdomen/chest CT scan will be performed every 3 month after surgery.
Study NCT00234039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT03997292 — intervention group
Intervention type: DRUG
Intervention: Urokinase
Description: 1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
Study NCT01642745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine (Provocholine)
Description: two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
Study NCT03284918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol ester
Study NCT03284918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04595994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
Study NCT04516395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined antibiotic regimens
Description: Combined antibiotic combinations defined as the optimal antibiotic combination regimens which are created from in vitro study and the application of PK/PD.
Study NCT04516395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard antibiotic regimens
Description: Standard antibiotic regimens defined as the antibiotic regimens which are generally given to the patients following to the hospital protocol.
Study NCT00864916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Description: Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
Study NCT03026348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1 Adjuvant
Study NCT00864916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination antiretroviral therapy (cART)
Description: Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
Study NCT00864916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
Study NCT00864916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo three times per day for 48 weeks.
Study NCT01642745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol (Aridol)
Description: single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
Study NCT01642745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine (Provocholine)
Description: two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
Study NCT01215916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636
Description: Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid \[350 micrograms (µg) to 1000 µg orally, daily\], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone \[4 milligrams (mg) orally, twice daily or equivalent\].
Study NCT01215916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 375 to 500 milligrams per square meter (mg/m\^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent).
Study NCT02061319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
Study NCT00934648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15
Study NCT00934648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25mg weekly
Study NCT02149849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified lateral positioning.
Description: Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
Study NCT01253811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
Study NCT00958438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
Study NCT00958438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
Study NCT00958438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
Study NCT02142387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BLS CPR program with dispatcher assisted CPR simulation
Description: the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
Study NCT01848782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpretation of the abstract of the systematic review
Study NCT01848782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interpretation of the abstract of the systematic review
Study NCT02328053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collagen crosslinking group
Description: collagen crosslinking with riboflavin and Ultraviolet A
Study NCT02328053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anti-fungal therapy
Description: topical antifungal medications like natamycin eye drops and voriconazole eye drops
Study NCT02328053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical anti-fungal therapy
Description: topical antifungal medications like natamycin eye drops and voriconazole eye drops
Study NCT04113590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Assisted Transvaginal Cholecystectomy
Description: Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
Study NCT01695876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 357
Description: Oral administration available in varying dose strength.
Study NCT01695876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AMG 357 containing no active drug
Study NCT04308031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg [Corlanor]
Description: Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
Study NCT04308031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin 0.25 mg
Description: Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60 Max dose: 0.25 once daily (QD)
Study NCT01446614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow derived mesenchymal stem cells
Description: Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
Study NCT02400164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alfapump system
Description: The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
Study NCT03782831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
Study NCT03782831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
Study NCT03782831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks
Study NCT03782831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: intravenous injection every 2 weeks
Study NCT04095585 — intervention group
Intervention type: GENETIC
Intervention: chromosomal microarray analysis (CMA) and whole exome sequencing (WES)
Description: The investigator evaluated the following hypotheses:~i) atypically large 7q11.23 deletions including additional genes; ii) rare pathogenic variants in genes located within the deletion, in particular GTF2I iii) additional pathogenic copy number variants (CNVs) or rare intragenic pathogenic variants located in other chromosomal regions with various inheritance patterns (autosomal recessive, X-linked, de novo autosomal dominant); given the small number of patients recruited, we focused on rare exonic variants considered to be pathogenic according to the criteria of the American College of Medical Genetics and Genomics (ACMG)
Study NCT00779259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline 300mg
Description: Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
Study NCT00779259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine 648 mg
Description: 648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
Study NCT00779259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline 300 mg
Description: Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
Study NCT00779259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine 648 mg
Description: 648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
Study NCT02858544 — intervention group
Intervention type: OTHER
Intervention: The Concussion Identification Index
Description: Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
Study NCT02858544 — intervention group
Intervention type: OTHER
Intervention: ImPACT
Description: Patient- completed computerized neurocognitive test battery
Study NCT03391193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-dose Quadrivalent Influenza Vaccine
Description: 0.5 mL, intramuscular
Study NCT03391193 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-dose Quadrivalent Influenza Vaccine
Description: 0.5 mL, intramuscular
Study NCT00879008 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
Study NCT00001131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Subcutaneous injection of IL-2 in the amount of 2.0 X 10\^6 mIU per day for the entire duration of therapy
Study NCT00001131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
Study NCT00001131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
Study NCT01984762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass
Description: RYGBP=Roux-en-Y gastric bypass
Study NCT01984762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: SG = sleeve gastrectomy
Study NCT00711516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
Study NCT00711516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
Study NCT01431209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01431209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT05456282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated mechanical peripheral stimulation
Description: Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
Study NCT05456282 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Automated mechanical peripheral stimulation
Description: Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
Study NCT05456282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
Study NCT05456282 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
Study NCT00626470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Addition of TSP to DHS
Description: All patients operated with DHS. Of these two groups. One operated with TSP and one without.
Study NCT00497809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-014 versus Filgrastim
Description: 3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
Study NCT00497809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVI-014 versus Filgrastim
Description: 3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
Study NCT01830400 — intervention group
Intervention type: DRUG
Intervention: Eslicarbazepine Acetate tablets
Description: The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
Study NCT03642704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reinforced preventive ARV therapy
Description: If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.
Study NCT03339297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: 6.25 mg/kg via 2-hour IV infusion every 6 hours
Study NCT03339297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Administered according to local institutional guidelines, physician preference, and patient need.
Study NCT03339297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Administered according to local institutional guidelines, physician preference, and patient need.
Study NCT04426695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered intravenously (IV) single dose
Study NCT02320201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulator (TENS)
Description: Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
Study NCT04426695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV Single Dose
Study NCT02688647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Study NCT02688647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BSC
Description: Treatment/drug as determined by each subject's prescribing physician
Study NCT03026348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phosphate Buffer
Study NCT01962038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Aerobic and Resistance Exercise
Description: Gym and home based aerobic and resistance exercises
Study NCT01962038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercises
Description: Gym and home based stretching exercises
Study NCT01962038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Group-based cognitive training